Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
https://doi.org/10.1186/s12967-020-02523-5
Funding for this research was provided by:
Merck Sharp and Dohme
National Institutes of Health (P01 CA190174)
National Cancer Institute (P01 CA190174)
Executive Committee on Research
Article History
Received: 23 June 2020
Accepted: 8 September 2020
First Online: 14 September 2020
Ethics approval and consent to participate
: This study has been approved by the Institutional Review Board (IRB). The approval is granted by The Office for Human Research Studies (OHRS) at the Dana Farber Harvard Cancer Center.
: Not applicable.
: O.Y has no competing interests.